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In a cross-sectional study, titers of antibodies to the 
E4 and E7 proteins of human papillomavirus (HPV) 
type 16 were measured by peptide-based enzyme-
linked immunosorbent assay in 1707 sera. Sera were 
obtained from healthy individuals (ages 1 to 95 years), 
from patients with HPV-associated infection (cervi-
cal intraepithelial neoplasia and cervical cancer), and 
from patients who were at high risk for HPV infection 
(attending a sexually transmitted disease clinic or 
referred to a colposcopist because of an abnormal 
Papanicolaou smear). The prevalence of anti-E7 an-
tibodies increased with age, although the overall 
prevalence in the adult population was low (10.36%) 
compared to the frequent detection ofHPV 16 DNA 
in the population. This suggests that only a fraction 
of patients infected with HPV 16 develop an anti-E7 
H uman papillomavirus (HPV) type 16 is detected frequently ill the gene ral population [1-4] and is closely associated with the development of cancer of the ute rine cervix [5). In about half of these tumors, HPV 16 genom es are presen t. A func-
tional role of the HPV 16 oncoproteins E6 and E7 in celI transfor-
mation has been demonstrated (fo r re views see [6 ,7]) . Human 
serum antibodies to the HPV 16 E6 and/or the E7 protein have 
been demon strated in a large proportion o f cervica l ca ncer pati ents 
w hose tumors con ta in HPV 16 DNA [8-10] . Antibodies to the E4 
protei n also have been found more frequently in such patients than 
ill controls without tu m ors. T he proportion of sera reactive with 
the E4 protein was lower than that reactive to the E6 o r E7 protein 
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response. The age distribution of anti-E4 antibodies 
showed a different pattern, i.e., the prevalence was 
low in the adult population (1.14%) but exceeded 20% 
in children and teenagers. As the specificity of the 
anti-E4 reaction was supported by a highly significant 
association with anti-E6 positivity in children's sera 
(p = 0.002), it was assumed that infection with HPV 
16 can occur frequently early in life. As compared to 
healthy controls, patients at high risk for HPV infec-
tion had a significantly higher frequency (p < 0.001) 
of antibodies to the HPV 16 E4 protein (but not to the 
E6 or the E7 protein) in their sera. Therefore, we 
conclude that in adults E4-specific antibodies may be 
a marker for virus replication. Key IIJOI'ds: age dislrib,,-
liollJCIN, ] Invest Dermato' 104:138-141, 1995 
[11 ,12]. It is unknown , however, whe ther antibodies to these HPV 
16 proteins are acquired during HPV 16 infection in normal 
individuals. W e illVestigated antibody prevalence to E4, E6, and E7 
prote ins in sera o btained from a large number of hea lthy individ-
ual s, frOI11 patients w ith HPV -associated di seases, and from patients 
w ith a h.igh ri sk of papiIJomavims in fection. W e report that the 
pattems of age-specific prevalence of antibodies agajnst the proteins 
E4 and E7 are quite different and that anti-E4 antibodies are more 
prevalent in patients with proven or suspected HPV infection. 
MATER.IALS AND M ETHODS 
Serum Donors Sera were obtained from blood donors at the University 
ofLciden, T he Netherlands (11 = 541); from hea lthy childrcn (n = 46) and 
adu lts (n = 54) in Maryland ; from children (n = 32), tecnagers (II = 55), 
and adu lts (n = 57) in Gerl1lan y; and from subjects in a case-control stud y 
of cervic,d canccr in Spain and Colombia p 3,1 4J: contro ls (n = 406). 
ccrvi cal cancer patients (n = 102), and p:ltients with high-gradc ce rvical 
intracpithcljal neoplasia (CIN) (n = 60), fi'om a Colposcopy C lin.ic (n = 
314) and from a sexuaU y transm itted diseasc (STD) C linjc (II = 40) . 
E nzyme Immunoassay With Synthetic Peptides Five synthetic pep-
tides were prepared for use in an enzymc- linked immunosorbe llt assay 
(ELISA) with human sera . T he peptides rcpresented one cpitopc on HPY 16 
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E4 (E4 aa33-47; Lys-Pro-Ser-Pro-Trp-A la-Pro-Lys-Lys-H is-Arg;-Arg-Leu-
Ser-Ser) , two on E6 (E6 aa l-23; Mct-His-Gln-Lys-Arg;-Thr-Ala-Met-Phe-
Gln-Asp-Pro-Gln-G lu-Arg;-Pro-A rg;- Lys-Leu-Pro-Gln-Leu-Cys and £6 
aa 8-3 7; M et- Phe-G I n-Asp- Pro-G In- Glu- Arg-l'ro- A rg- Lys- Leu- Pro-
Gln-Lc u-Cys-Thr-Glu- Le u- Gln- T hr- T hr - ll e- Hi s-Asp-Il e- ll e- Leu-
Gl u-Cys). and two on E7 (E7 aa6-35: Pro-T hr-Leu-His-G lu - Tyr-Mct-
Leu-Asp-Leu- Gin - Pro- GlLt - T hr- Thr- Asp - Leu- Tyr- Cys - Tyr- Glu -
Gln -Leu -Asn-Asp-Scr-Ser-Glu- Glu -G lu and E7 aa29-52; Asn-Asp-
Ser-Ser-G lu-G lu-G lu - Asp-G lu- Il e-Asp-G ly-Pro-A la-G I y-G I n-A la-G lu-
Pro-Asp-Arg;-Ala-His-Tyr). T he epitopcs were identified by screening; a 
phag;c library. as described earlier /15] . Automated peptide syllthesis was 
performed with a Millig;en / Biosearch model 9050 peptide synthesizer 
according to protocols specified by the manuf:tcturer. The purity of the 
peptide was verified by ana lytica l reverse-phase high performance liquid 
chromatography using a Vy-dac C 18 column. Wells of microtiter plates 
(Iml1lunol II. Dynatech Laboratories, Arlington . VA) were co'ated with 10 
ILg/ ml of £7 aa6-35 or 30 ILg/ml of £7 aa29-52 in phospha te-b ufl'C red 
sa line, pH 7.2, or with 30 ILg/ ml E4 a333-47 or 25 ILg/ml £6 aa l -23 or 10 
ILg/ml E6 aa8-37 in 0.06 M carbonate bufFer. pH 9.6. Serum specimens 
were tested in duplicate at a 1 :25 dilution . T he assay was cOl1lpleted with a 
goat anti-human Ig;G conjugated to horser<tdish peroxidase (Zymed Labo-
ratories, San Francisco, CA l and A13TS 12.2' -azino-bis(3-ethylbenz-thiazo-
line-6-su lfonic acid}] substrate so lution. For each serum, the mean reactivity 
of bufFer-coated weLls was subtracted fro m the mean reactivity of wells 
coated with peptide to calculate a net absorbance value. Individual sera 
were scored antihody-pos itive or antibody-neg;ative for each peptide using 
a cutoWabsorbance va lue tha t was based on the distribution of absorbance 
va lues of the control sera (hea lth y adults of each investigated serum 
co llection) excluding; the outli ers. T he means and standard dev ia tions (SOs) 
of absorbance va lues of control sera were ca lculated, and se ra with va lues 
greater than a mean + 3 SO were excl uded. T he means and SDs then were 
recalculated and additiona l se ra excl uded. if necessary, by tl,e same criteria. 
T his process was repeated until none of the remainin g; se ra were excluded. 
and the fi nal mean + 3 SO was taken as the cutolf va lue. 
T he statistica l analysis compa red proportions of positive sera using the X2 
test of independence and. in cases of small sample sizes, the Fisher exact test. 
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Two-sided alpha levels of less than 0.05 were considered statistically 
sign ificant: no adjustments were made for multiple statistical testing. 
RESULTS 
A tota l of 1707 hum an sera were tested in an ELISA for antiboclies 
to peptides d e rived from seroreactive regions of HPV 16 E6 (two 
peptides), E7 (two peptides), and E4 (one peptide). The collection 
consisted of 1191 sera of healthy individuals (78 children , 1 to 10 
yea rs; 61 tee nagers, 11 to 20 yea rs; 1052 adu lts, 2 1 to 95 years), se ra 
of 60 patie nts with CIN and of I 02 patients with cervical cancer, 40 
sera of patients attending an STD clinic, and 314 sera from patients 
who were referred to a colposcopist beca use of all abnormal 
Papanicolaou smear ("colposcopy patients"). Sera reacting with 
any E6 o r E7 peptid e were conside re d E6- or E7-positive, respec-
tive ly. 
Reactivity to HPV 16 E4, E6, and E7 in a Group of Healthy 
Individuals Sera of h ea lthy individuals were obtained from 
different populations, i.e. , Germany, Maryland . Spain/ Colombia, 
and T he Netherlands (see Materials ami Methods; Fig lA-D) . Not all 
age groups are represented (i'om each country; however, compar-
ative analysis of all sera (Fig 1E) is justified because no statistically 
signi ficant difFerences in antibody prevale n ce were detected upon 
compa ring the following populations: Germany with Maryland in 
the age gmup 0 to 10 yea rs, Gennany w ith The Nethe rlands with 
Colombia /Spain (age gmup 21 to 30 yea rs) , Germany with The 
Netherlands with Colombia/ Spai n (age groups 30 to 70 yea rs) , and 
Maryland with Colombia / Spain (age gmup o lder than 70) . 
Tests w ith se ra from 1191 hea lthy individual s (ages 1 to 90 years) 
revea led different prevale nces of anti-I-IPV-16 E4 and E7 antibodies 
in the ind iv idu al age groups (Fig 1 E). No significant difference was 
observed in the prevalences of anti-H PV -16 antibodies when males 
and tc males of the contml g roup were compared (data not shown) . 
Among adults (ages 2 1 to 95 yea rs; n = 1052). the rea ctivity to 
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F igure 1. Antibodies to the HPV 16 E4 and E7 proteins have different age-specific patterns. The seroprevalcnce (given as percent positive sera) 
by age of HPV 16 E4- alld E7-specific all tibodies was measured ill 11 91 sera fi'om foul' diffel'ellt popula60ns (Gen1lall),. A: Marylalld. 13: T he Netherlands. 
C; Colombia /Spain , D; ' ul1lulative data by age g;roup. E:.). 
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HPV 16 E4 was 1.14%. In the various age groups of the adults, the 
prevalences ranged from 0% (51 to 60 years) to 3.0% (71 to 80 
years). T hese differences were not sta tisticaUy significant. The 
highest freq uencies of 3nti-E4-positive se ra were fo und in th e 
g roup of 78 children (ages 1 to 10 years; 26 .9% positive sera) and 
the 61 teenagers (ages 11 to 20 years; 24.6% positive sera) . T he 
preva.lence of anti-HPV-16 E4 antibodies was signifi cantly higher 
among chiJdren an d tcenagers than among adul ts over age 20 years. 
A subset of the children 's sera (Maryland, n = 46; 30.4% E4-
positive) also was tested for the presence of anti-HPV-16 E6 
antibodies; we found a twofold increase compared to the sera from 
405 hea lthy adults from Colombia/Spain (10 .9% compared to 
4.4%; p = 0.06). The five sera positive for E6 antibodies were also 
positive for E4 antibodies. T his correlation was statistically signifi-
cant (p = 0.002; Fig 2) . 
Reactivity to either or both peptides derived from HPV 16 E7 
amounted to 9.45% of all sera tes ted from healthy individuals. The 
pattern ofE7 reactivity differed significantly across age groups (p = 
0.03): children and teenagers displaycd very few reactive sera (2.5% 
and 1.6%, rcspectively), w hereas a signifi cantly greater proportion 
(10.36%) of the 1052 sera frOI11 the hca lth y adults was shown to be 
positive. A gradual increase frol11 9.5% to 13% in the prevalence of 
anti-E7 antibodies was o bserved for th e age groups from 21 to 60 
years, fo llowed by a significant decEne to 8.3% and 3.0% in the age 
groups of 61 to 70 and o ldcr than 70 years, respectively. 
Reactivity to HPV 16 E4, E6, and E7 in Sera of Patients at 
High Risk for HPV -Associated Diseases To investigate a 
possible correlation of specific antibodies with HPV-associated 
diseases, sera from patients with C IN , fro m patients attending a 
cEnic for STDs, and frO I11 colposcopy patients were screened fo r 
antibodies to HPV 16 E4, E6, and E7. The results are smnmarized 
in Table I . 
W hereas a low prevalcnce was found for antibodies to HPV 16 
E4 in sera fi'om health y adults, a hi gher reactivity was obscrved in 
sera from colposcopy paticnts (16.2'% positive sera ; p < 0.001) and 
in sera from STD patients (10% positive sera; p < 0.001) . In 
contrast, antibodics aga inst HPV 16 E6 and E7 were not found 
more freq uently in the two patient groups compared to the 
controls. The differcn t reactivity aga inst E7 in the g roup of STD 
E4 E6 
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Figure 2 . Coincidence ofE4- and E 7-specific antibodies in children. 
Sera of 46 chiJdrcll werc tested for allti-E4' antibodies (I'iii) and 3nti-E6 
antibodies (rigltl; reactivity against thc peptide E6 33 1-23) . On both sides, the 
samc scra are shown in idcntica l positions. All sera scored positive for E6 (x) 
reactcd significantly with the E4 peptide. 
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Table I. Prevalence of Anti- HPV-16 E4, E6, and E7 
Antibodies in Sera of Patients at Risk for HPV -Associated 
Diseases and in Controls" 
E4-Positivc E6-Positive E7-Positive 
STD (11 = 40) 
Colposcopy (n = 314) 
Controls (ages 1 to 80 y; n = 11 91) 
10.0% 
16.2% 
3.63%/' 
5.0% 
4.4%, 
5.·14'){( 
5.0% 
10.5% 
9.45'Yo 
"Sera of patients with I-IPV-associatcd diseases and of healthy contro ls were 
screened fo r antibodies against pcptidcs deri ved frOI11 HPV 16 E4 (one peptide), E6 
(reactivity with at least one of two E6 peptides), and £7 (reactivity with at least a il e of 
two E7 peptide,). 
b T he preva lell ce of an ti-E4 antibodies was I. 14% in the adults (ages 21 to 80 years) 
of the control popuhltion. 
r T he pre valence of anti-E6 antibodies in the sera of 452 hea lthy controls (406 <1du lts 
nnd 46 chi ldren) . 
patients (5.0%) compared to the contro ls (9.45%) w as not statisti_ 
cally significant. 
We detected a sEghtIy higher, significantly different (p = 0.02) 
prevalence of anti-E4 antibodies in the sera of patients with HPV-16-
positive invasive cervical carcinomas (four of 102 patients; 3.9°;(,) as 
compared to healthy adults (n = 1052, 1.14%). Of the E4-positive 
cancer patients, only one reacted also with E7. In patients with 
high-grade, HPV-16-positive CIN (n = 60), only one anti-E4-
positive serum (1 .7%) was found . 
DISCUSSION 
In tills study, antibodies to the nonstructural proteins E4, E6, and E7 
of HPV 16 were measured in sera of patients with proven or 
suspected HPV-associated discases in comparison to age-matched 
controls, and their age-dependent prevalences in healthy people 
were determined. W e observed differen t prevalences of anti-E4, 
-E6, and -E7 antibodies in th e individual groups of patients and 
controls, indicating different patte rns of expression of these prote ins 
or different presentations to the immune system during the course 
of HPV 16 infections. 
Compared to healthy adults, HPV 16 E4-specific antibodies were 
o bserved more frequently in patients with STDs and in WOmen 
who were rcfcrred to a colposcopy clinic beca use of an abnormal 
Papanicolaou smear. Although th e patients were not tested for HPV 
infecti on, both groups have a high probability for acute or past HPV 
16-associated lesions [16,17], suggestin g tha t E4 an tibodies may be 
a marker fo r virus rep\1cation . We are planning to study paticnts 
from whom both serum and viral DNA from genital swabs o r from 
I-IPV-associa ted lesions are avai lable for testing. It is possiblc tha t 
the prevalcnce ofE4 reactivity wi ll be even higher among HPV-16 
DNA-positive patients. 
In ea rlieJ· investigations , we showed that detecti on of antibodics 
aga iJlst HPV 16 E6 and E7 was strongly corre lated with the 
presence of HPV 16 DNA in patients with cerv ical carcin omas. 
T his type specificity is consistent with the persistcnt HPV 16 
infection in thcse patients [10] . The slightly higher prcva lence of 
anti-HPV-1 6 E4 antibodies in ccrvi cal cancer pa tients , as o bserved 
origina1ly by Jochmus-Kudielka ei al [8) and confirmed by this 
study, ma y be explaiJlcd either by continu o us expression of the E4 
protein in some cervical carcinomas evcn in the abscnce of virus 
production, or by a concurrent presence of virus producing benign 
cervical lesions in those paticnts, as also suggested ea rlier [1:1 ,12] . 
T he fact that 3nti-E6 and anti-E7 antibodies were not dctected 
more frequently in the STD and colposcopy patients as compared to 
the healthy indi viduals indicates that these proteins usually do not 
stimuJate the immunc system dUling viral replication. T his could be 
due to eithe r low production of these proteins o r poor contact to 
the immune system during the vira l replication cycle. T he presence 
of E6- o r E7-spccifi c antibodies in a sma ll number of heal thy 
individu als may indicate that these subjects have a persistent HPV 
infection, and prolonged expos ure of th e immune system to thcse 
proteins may overcome their low immunogenicity. O n the oth er 
VOL. 104. NO. J ANUARY 1995 
hand, we cannot exclude the possibility that antibodies elicited as a 
response to infections with other papillomaviruses cross-reacted in 
the peptide ELISA in this study. 
The group of healthy individuals showed different age-depen-
dent preval ences of anti-E4 and anti-E7 antibodies. In children and 
teenagers, E7-specific antibodies were found on ly rarely, and a 
plateau of 8% to 13% positive sera was reached in the adult 
population . Sera fi'om elderly people demonstrated a decline of 
reactiv ity. The detection of measurable antibodies in only a small 
proportion of hea lthy people and of the patients with exposure to 
HPV infection suggests that the E7 protein has low iIl1Il1unogenicity 
in most individuals. Even in patients with HPV-16-positive cervi-
cal cancer, assumed to be exposed to substantial levels of the E7 
protein, a proportion of women f.~i l to develop E7-specific anti-
bodies [1 0]. 
The frequent detection of anti-E4 antibodies in the younger age 
groups, especiall y in children 1 to 10 years of age, was sUI·prising. 
T he specificity of the reaction and the significance of this result are 
not clear. However, it is unlike ly that the peptide ELISA detected 
cross-reacting antibodies directed to an antigen that is ul11'elated to 
HPV, beca use a strong concordance was observed between E4- and 
E6-specifi c antibodies within the sam e sera (Fig 2). Because the E4 
open reading fi':1mes are the least conserved among the different 
papilloma viru ses, cross-reacting antibodies directed to the E4 pro-
teins of o ther HPV types, creating fa lse-positive results , also are 
unlike ly. In view of the heterogeneity of HPVs , however, such 
cross-reactivity with any other HPV type cannot be excluded in all 
instances . Ifi ndeed type-specific anti-HPV-16 antibodies are m ea-
Sllred in children , infec tion with HPV '16 (or a closely related 
papillomavirus) must be assumed to be fa irly frequent already at a 
young age. Indeed, HPV 16 DNA was detected recently by 
polymerase chain reaction in genita l or oral swabs obta ined fi'om 
infants ([1 8]; K. Mund and L. Gisslllann, unpublished data). IfHPV 
16 infection is prevalent in children, o ne has to assume that 
transmissio n usually occurs by nonsexual routes , e.g., perina ta lly (as 
reported for HPV 11) or by skin contact dlll'ing child care [19]. 
The biologic consequences of HPV 16 in fection in in fants are 
completely unknown. O nly follow-up studies, including screening 
for IgM-type antibodies, will unravel to w hat extent seroconver-
sion is correlated to cliJli cally detecta ble in fections and wh ether 
childhood infection by HPV 16 confers imlllunity to later exposure 
or otherwise inAuen ces the manifestation of sexual acquired pap il-
lomaviru s infections. The latter aspect is particu larly important 
beca use ea rl y age at first intercourse is considered a signifi cant I;sk 
factor for the deve lopment of cervical cancer. 
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